In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey

Basit Öğe Kaydı
dc.authorid0000-0001-8646-2203en_US
dc.authorid0000-0001-7966-3234en_US
dc.authorid0000-0002-9400-0997en_US
dc.authorid0000-0002-2081-4664en_US
dc.authorid0000-0002-8163-1386en_US
dc.authorid0000-0002-6054-9244en_US
dc.authorid0000-0003-0442-5981en_US
dc.contributor.authorYıldırım, Figen Sarıgül
dc.contributor.authorÜser, Ülkü
dc.contributor.authorSarı, Nagehan Didem
dc.contributor.authorKurtaran, Behice
dc.contributor.authorÖnlen, Yusuf
dc.contributor.authorCan, Güray
dc.contributor.authorSırmatel, Fatma
dc.date.accessioned2023-09-11T08:38:07Z
dc.date.available2023-09-11T08:38:07Z
dc.date.issued2022en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naive patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.en_US
dc.identifier.citationYıldırım, F. S., Üser, Ü., Sarı, N. D., Kurtaran, B., Önlen, Y., Şenateş, E., ... & Tabak, F. (2022). In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. The Turkish Journal of Gastroenterology, 33(11), 971.en_US
dc.identifier.doi10.5152/tjg.2022.21834
dc.identifier.endpage978en_US
dc.identifier.issn2148-5607
dc.identifier.issue11en_US
dc.identifier.pmid36415900en_US
dc.identifier.scopus2-s2.0-85142524509en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage971en_US
dc.identifier.trdizinid1175267en_US
dc.identifier.urihttp://dx.doi.org/10.5152/tjg.2022.21834
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11689
dc.identifier.volume33en_US
dc.identifier.wosWOS:000898674900009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorCan, Güray
dc.institutionauthorSırmatel, Fatma
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDrug Therapyen_US
dc.subjectDrug Usersen_US
dc.subjectHepatitis C Virusen_US
dc.subjectOpioid Agonist Treatmenten_US
dc.subjectVirus-Infectionen_US
dc.subjectGenotype Distributionen_US
dc.titleIn a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
figen-sarigul-yildirim.pdf
Boyut:
2.04 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu